China Regenerative Medicine International Ltd (8158) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of China Regenerative Medicine International Ltd stock HK$0.72, price HK$0.25, upside +193.9%, quality 59 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.
How to read this chart
60‑month range HK$0.0940 – HK$4.10 · fair‑value band HK$0.5200 – HK$0.9000 · the HK$0.2450 price screens below the HK$0.7200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 1, 2026.
Follow China Regenerative Medicine International in your weekly email
Every Wednesday you see whether China Regenerative Medicine International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
China Regenerative Medicine International Limited, together with its subsidiaries, engages in the research, development, production, and sale of tissue engineering and regenerative medicine products in Hong Kong and China.
Show moreShow less
It operates in two segments, Aesthetic Medical and Beauty Services, and Medical Services.
The company offers anti-aging /prevention, functional medicine and solutions, and treatment and diagnosis; hair regenerating medical solutions; and zoom consultation, mental fog therapy, physiotherapy, acnes treatment, and facial and slimming acupuncture services.
It also provides skin regeneration, body function refining, Chinese/medical aesthetics, slimming and detoxing, and uterine and circulation services; endoscopy and scar removal services; and medical tests and vaccines.
The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in February 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Tsim Sha Tsui, Hong Kong.
Stock analysis
China Regenerative Medicine International Ltd (8158) currently trades at HK$0.2450, while our model-based Fair Value estimate is HK$0.7200, implying the stock looks roughly 66.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$2.80 per share, and 17 of the 21 models we run sit above the HK$0.2450 price.
Bear case: the Asset-Based group reads lowest at HK$0.1100, and 4 of the 21 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$0.5200 (bear) to HK$0.9000 (bull), the price of HK$0.2450 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
China Regenerative Medicine International Ltd reported revenue of HK$72.1M in FY2025 versus HK$283M in FY2021, a compound −29.0%/yr. Reported net income was HK$27.5M in FY2025, compounding −14.6%/yr from FY2021.
Key figures
Market cap HK$74.5M (≈ $9.5M) Micro · P/E ratio 2.7 · P/S ratio 1.04 · Net margin 38.2% · Return on equity 64.2% · Return on assets (EBIT) −3.8% · Operating margin 13.1% · Revenue (TTM) HK$86.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 80 out of 100 (low confidence).
What moves the price
The share trades about 61% below its 52-week high and 36% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 194%, 8158 screens cheaper than that median.
Fair Value models
BearHK$0.5200Fair Value HK$0.7200BullHK$0.9000
Price HK$0.2450 · Upside +193.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−31.6%
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
’12
’14
’15
’16
’17
’18
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+14.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−23% → −2%
2025 sits 144% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +12.0% a year for the price.
Compare China Regenerative Medicine International Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks
Beats the industry median on 12/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score59 · Top 25%
Fair Value upside+193.9% · Top 25%
Profitability
Return on equity (12 months)64.2% · Top 25%
Return on assets16.4% · Top 25%
Net margin (12 months)31.9% · Top 25%
Operating margin (12 months)13.1% · Above median
Growth and dividend
Revenue growth (quarter YoY)52.4% · Top 25%
Balance sheet
Debt / equity0.50× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "China Regenerative Medicine International Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8158
Frequently asked questions
Is China Regenerative Medicine International Ltd (8158) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of HK$0.7200 versus a price of HK$0.2450, about +194% upside (undervalued).
What is the fair value of 8158?
Our model-based fair value for China Regenerative Medicine International Ltd is HK$0.7200 (as of Nov 1, 2026), built from audited fundamentals. The current price: HK$0.2450.
What is the quality score of 8158?
China Regenerative Medicine International Ltd has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for China Regenerative Medicine International Ltd (8158)?
Our model-based price target is the fair value of HK$0.7200 (as of Nov 1, 2026) from 21 valuation models. Cautious scenario HK$0.5200, optimistic scenario HK$0.9000. It is a calculation from audited fundamentals, not an analyst target.
What is the China Regenerative Medicine International Ltd stock forecast for 2026?
Our models put fair value at HK$0.7200, about +194% upside versus a price of HK$0.2450 (undervalued). Cautious scenario HK$0.5200, optimistic scenario HK$0.9000. The calculation is refreshed regularly with new filings.
What is the revenue of China Regenerative Medicine International Ltd (8158)?
China Regenerative Medicine International Ltd reported trailing-twelve-month revenue of about HK$86.4M (latest available figure, as of Nov 1, 2026).
What growth is priced into China Regenerative Medicine International Ltd (8158)?
For today's price to be fair in a discounted-cash-flow model, China Regenerative Medicine International Ltd would have to grow free cash flow by +14.4 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -16.9 % per year. As of Nov 1, 2026.
What discount rate (WACC) does the fair value of 8158 use?
Our models discount China Regenerative Medicine International Ltd at 10.3 %: a base by market capitalisation (nano), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For China Regenerative Medicine International Ltd that is +14.4 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has China Regenerative Medicine International Ltd (8158) delivered so far?
Over the past 5 years revenue at China Regenerative Medicine International Ltd grew -16.9 % a year. The price currently implies +14.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of China Regenerative Medicine International Ltd (8158) growing?
The median revenue growth in the sector is +6.4 % a year. That is the yardstick for the growth priced into China Regenerative Medicine International Ltd (+14.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of China Regenerative Medicine International Ltd (8158)?
The free-cash-flow yield on the price is 5.40 %: that much free cash flow China Regenerative Medicine International Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of China Regenerative Medicine International Ltd (8158)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Regenerative Medicine International Ltd it is HK$0.7200 per share (as of Nov 1, 2026), against a price of HK$0.2450. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is China Regenerative Medicine International Ltd stock overvalued or undervalued in 2026?
As of Nov 1, 2026, 8158 trades below its calculated fair value: price HK$0.2450, fair value HK$0.7200, a gap of about +194% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8158?
No. The price is what the market pays today (HK$0.2450); the fair value is what the company's own numbers justify (HK$0.7200). For China Regenerative Medicine International Ltd the two are HK$0.4750 per share apart. That gap is exactly why we show both numbers side by side.
How much is China Regenerative Medicine International Ltd worth?
The market values China Regenerative Medicine International Ltd at about HK$74.5M (market capitalisation, as of Nov 1, 2026). Per share that is HK$0.2450; our models calculate a fair value of HK$0.7200 per share.
What do the bullish and bearish scenarios say about 8158?
Our models span a range for China Regenerative Medicine International Ltd: cautious scenario HK$0.5200, base HK$0.7200, optimistic HK$0.9000 per share (as of Nov 1, 2026, price HK$0.2450). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 8158?
China Regenerative Medicine International Ltd trades at a price-to-earnings ratio of 2.7 (as of Nov 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.7200 is built from several models across several years. Other multiples: P/B 1.4, P/S 0.9, EV/EBITDA 10.6.
How solid is the balance sheet of China Regenerative Medicine International Ltd (8158)?
Balance-sheet figures for China Regenerative Medicine International Ltd (as of Nov 1, 2026): return on equity 64.2%, debt of 0.50 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 8158 from its 52-week high?
China Regenerative Medicine International Ltd trades at HK$0.2450, about 61% below its 52-week high of HK$0.6300 and 36% above the low of HK$0.1800 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.7200 is for.
Which stocks are comparable to China Regenerative Medicine International Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is China Regenerative Medicine International Ltd stock attractive at the current price?
The data as of Nov 1, 2026: price HK$0.2450, calculated fair value HK$0.7200 (+194%), Quality Score 59/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8158 calculated?
We run China Regenerative Medicine International Ltd through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.7200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. China Regenerative Medicine International Ltd currently trades 66 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of China Regenerative Medicine International Ltd (8158)?
The closing price on Oct 30, 2026 was HK$0.2450. Our model-based fair value is HK$0.7200, about +194% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with China Regenerative Medicine International Ltd right now?
The price is below even our cautious bear case (HK$0.5200). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (59/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of China Regenerative Medicine International Ltd
How large is the market capitalisation of China Regenerative Medicine International Ltd (8158)?
The market capitalisation of China Regenerative Medicine International Ltd is HK$74.5M (≈ $9.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of China Regenerative Medicine International Ltd (8158)?
The price-to-sales ratio of China Regenerative Medicine International Ltd is 1.04 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of China Regenerative Medicine International Ltd (8158)?
The net margin of China Regenerative Medicine International Ltd is 38.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of China Regenerative Medicine International Ltd (8158)?
The return on equity (ROE) of China Regenerative Medicine International Ltd is 64.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of China Regenerative Medicine International Ltd (8158)?
On an EBIT basis the return on assets of China Regenerative Medicine International Ltd is −3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of China Regenerative Medicine International Ltd (8158)?
The operating margin of China Regenerative Medicine International Ltd is 13.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at China Regenerative Medicine International Ltd (8158)?
Revenue at China Regenerative Medicine International Ltd is growing +52.4% versus a year earlier (3y avg −31.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does China Regenerative Medicine International Ltd (8158) carry?
The net debt of China Regenerative Medicine International Ltd is HK$43.1M (fiscal year 2025, ≈ 10.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch China Regenerative Medicine International Ltd in the live analysis
One click puts China Regenerative Medicine International Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 1, 2026